替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者30例临床观察

发布时间：2018-06-03 08:56

本文选题：慢性乙型肝炎 + 乙型肝炎E抗原　；参考：《中医杂志》2015年22期

【摘要】：目的观察替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者的临床疗效。方法将60例E抗原阳性慢性乙型肝炎患者随机分为治疗组和对照组各30例。对照组给予替比夫定片,每次600 mg,每日1次,口服;治疗组在对照组基础上给予当飞利肝宁胶囊,每次1.0 g,每日3次,口服。分别在治疗前及治疗后12周、24周时观察两组患者HBV DNA定量、肝功能[包括总胆红素(TBiL)、丙氨酸氨基氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)]、肝纤维化指标[包括血清透明质酸(HA)、层粘蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(CL-Ⅳ)]、肝脏瞬时弹性的改变。结果治疗后12周及24周两组患者HBV DNA定量、肝功能、肝脏瞬时弹性及HA、LN、PC-Ⅲ、CL-Ⅳ水平均较治疗前下降(P0.05)。治疗后24周与12周比较,两组患者HBV DNA定量、肝功能、肝脏瞬时弹性及HA、LN、PC-Ⅲ、CL-Ⅳ水平亦明显下降(P0.05)。两组患者治疗后12周及24周HBV DNA定量和肝功能组间比较差异均无统计学意义(P0.05)。治疗组肝脏瞬时弹性和HA、LN、PC-Ⅲ、CL-Ⅳ水平治疗后12周及24周时较对照组明显下降(P0.05)。结论替比夫定片联合当飞利肝宁胶囊治疗E抗原阳性慢性乙型肝炎患者,不仅可以有效改善肝功能指标,控制HBV DNA水平,同时明显改善肝脏纤维化和肝脏瞬时弹性,延缓疾病进展。
[Abstract]:Objective To observe the clinical efficacy of Telbivudine Tablets combined with floral Ligan Ning Capsule in the treatment of E antigen positive chronic hepatitis B patients. Methods 60 patients with E antigen positive chronic hepatitis B were randomly divided into treatment group and control group (30 cases each). The control group was given Telbivudine Tablets, 600 mg each time, 1 times a day, oral administration, and the treatment group was on the basis of the control group. 1 g each time, 3 times a day, and 3 times a day, respectively, were given in two groups of patients (including total bilirubin (TBiL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and liver fibrosis index [including serum hyaluronic acid (HA), and laminin (including serum hyaluronic acid (HA) and laminin). (LN), type III procollagen (PC- III), type IV collagen (CL- IV), transient elasticity of the liver. Results 12 weeks and 24 weeks after treatment two groups of patients with HBV DNA quantitative, liver function, liver instantaneous elasticity and HA, LN, PC- III, CL- IV levels were lower than before treatment (P0.05). 24 weeks and 12 weeks after treatment, two groups of HBV DNA quantitative, liver function, liver momentary projectile The levels of sex and HA, LN, PC- III, and CL- IV were also significantly decreased (P0.05). There was no significant difference between the HBV DNA quantitative and liver function groups in the two groups after 12 and 24 weeks of treatment (P0.05). The liver instantaneous elasticity and HA, LN, PC- III, CL- IV level after 12 and 24 weeks after treatment in the treatment group were significantly lower than those of the control group. Conclusion Telbivudine Tablets combined with the control group. The treatment of E antigen positive chronic hepatitis B patients with flanligan capsule can not only effectively improve the liver function index, control the level of HBV DNA, but also improve the liver fibrosis and the instantaneous elasticity of the liver, and delay the progression of the disease.
【作者单位】：东南大学附属第二医院;
【分类号】：R512.62

【参考文献】